ORIC Pharmaceuticals reported potential best-in-class results for its allosteric PRC2 inhibitor, rinzimetostat, in metastatic castration-resistant prostate cancer. In combination with approved androgen receptor inhibitors, the agent achieved prostate-specific antigen (PSA) reductions of 50% or greater in 55% of evaluable patients and PSA reductions of 90% or greater in 20%. Molecular tumor burden assessments showed circulating tumor DNA clearance in 59% of participants. Safety data revealed a differentiated profile with mostly low-grade adverse events and no new safety signals, supporting further development of the asset in registrational settings. ORIC expects to report combination dose optimization data in the first quarter of 2026 and to initiate its first global Phase 3 registrational trial in mCRPC in the first half of 2026.

At the same conference, ORIC highlighted Phase 1b data for enozertinib in patients with EGFR exon 20 insertion mutations, demonstrating an objective response rate of 67% in first-line therapy and a 100% intracranial response rate in those with measurable central nervous system disease. These results reinforce the molecule’s potential best-in-class profile in lung cancer. Management also announced an extension of the company’s cash runway into the second half of 2028, following a combination of equity financings and operating efficiencies, and detailed recent hires in clinical development and regulatory affairs to support upcoming registrational filings across both lead programs.